晚期NSCLC治疗的变革.pptVIP

本文观看结束！！！ * This has translated into meaningful prolongation in survival. The slide depicts the survival of ALK-Positive NSCLC Patients treated with Crizotinib on the Expansion cohort of the Phase 1 trial from 2008 to 2010 and reported at the ASCO meeting this week. The estimated actuarial survival of the 82 patients show 74% alive at 1 year and 54% alive at two years. The median is not yet reached. * MAb, monoclonal antibody; NSCLC, non-small-cell lung cancer; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PS, performance status; q3w, every 3 weeks; q